Semaglutide in MASH with F2-F3 fibrosis: a holistic perspective on the ESSENCE phase 3 trial | ||
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas | |
| dc.conicet.organizacion | Universidad Maimónides. Facultad de Ciencias de la Salud. Centro de Investigación Traslacional en Salud | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas | |
| dc.conicet.organizacion | Universidad Maimónides. Facultad de Ciencias de la Salud. Centro de Investigación Traslacional en Salud | |
| dc.contributor.author | Pirola, Carlos Jose | |
| dc.contributor.author | Sookoian, Silvia Cristina | |
| dc.date.issued | 2026-04 | |
| dc.description.abstract | Metabolic dysfunction-associated steatohepatitis (MASH) with significant fibrosis (F2-F3) is a critical stage of metabolic dysfunction-associated steatotic liver disease (MASLD), during which intervention may avert transition to cirrhosis, hepatocellular carcinoma, and liver-related death. The phase 3 ESSENCE trial (NCT04822181) evaluated once-weekly subcutaneous semaglutide 2.4 mg vs. placebo over 240 weeks in adults with biopsy-confirmed MASH and F2-F3 fibrosis. A prespecified interim histologic assessment was performed at week 72 among the first 800 randomized participants. Semaglutide increased MASH resolution without worsening fibrosis and significantly increased the proportion of individuals achieving ≥ 1-stage fibrosis improvement compared with placebo, with a clinically meaningful number needed to treat. These histologic effects coincided with substantial weight reduction (~10%-11% vs. ~2% with placebo) and broad improvements in cardiometabolic risk profiles, including glycemia, blood pressure, lipid levels, and inflammatory biomarkers. Favorable shifts were also observed in non-invasive assessments, including the enhanced liver fibrosis score, vibration-controlled transient elastography, N-terminal type III Collagen Propeptide (PRO-C3), FibroScan-AST (FAST) score, and aminotransferases. Safety outcomes were consistent with the established semaglutide profile in type 2 diabetes and obesity. Here, we critically appraise ESSENCE from clinical and translational perspectives and consider the relative contributions of weight loss vs. potential weight-independent mechanisms. Semaglutide was also situated among emerging latestage therapies, including resmetirom, a thyroid hormone receptor β agonist with demonstrated antifibrotic and antisteatohepatitic activity. Finally, we outline the implications of adopting semaglutide as a disease-modifying agent in MASH with F2-F3 fibrosis, note the study limitations and remaining questions, and argue that combinatorial approaches targeting complementary metabolic and hepatocentric pathways may define the next phase of MASLD management. | es |
| dc.description.fil | Fil: Pirola, Carlos Jose. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Maimónides. Facultad de Ciencias de la Salud. Centro de Investigación Traslacional en Salud; | |
| dc.description.fil | Fil: Sookoian, Silvia Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Maimónides. Facultad de Ciencias de la Salud. Centro de Investigación Traslacional en Salud; | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Pirola, Carlos Jose; Sookoian, Silvia Cristina; Semaglutide in MASH with F2-F3 fibrosis: a holistic perspective on the ESSENCE phase 3 trial; OAE Publishing Inc.; Metabolism and Target Organ Damage; 6; 2; 4-2026; 1-9 | es |
| dc.identifier.eissn | 2769-6375 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/286536 | |
| dc.journal.ciudad | Los Angeles | es |
| dc.journal.number | 2 | es |
| dc.journal.pagination | 1-9 | es |
| dc.journal.pais | Estados Unidos | es |
| dc.journal.title | Metabolism and Target Organ Damage | es |
| dc.journal.volume | 6 | es |
| dc.language.iso | eng | es |
| dc.publisher | OAE Publishing Inc. | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://www.oaepublish.com/articles/mtod.2026.13 | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.20517/mtod.2026.13 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by/2.5/ar/ | * |
| dc.subject | CLINICAL TRIAL, PHASE 3 | es |
| dc.subject | GLP1R AGONISTS | es |
| dc.subject | SEMAGLUTIDE | es |
| dc.subject | MASLD | es |
| dc.subject | MASH | es |
| dc.subject | LIVER FIBROSIS | es |
| dc.subject | TREATMENT | es |
| dc.subject.classification | Gastroenterología y Hepatología | es |
| dc.subject.classification | Medicina Clínica | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.subject.classification | Farmacología y Farmacia | es |
| dc.subject.classification | Medicina Básica | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | Semaglutide in MASH with F2-F3 fibrosis: a holistic perspective on the ESSENCE phase 3 trial | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.67c6d8b5-03a8-4c8b-8202-6ecc3d99d91c_B.pdf
- Tamaño:
- 5.65 MB
- Formato:
- Adobe Portable Document Format